GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Curatis Holding AG (XSWX:CURN) » Definitions » LT-Debt-to-Total-Asset

Curatis Holding AG (XSWX:CURN) LT-Debt-to-Total-Asset : 0.00 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Curatis Holding AG LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Curatis Holding AG's long-term debt to total assests ratio for the quarter that ended in Jun. 2024 was 0.00.

Curatis Holding AG's long-term debt to total assets ratio declined from Jun. 2023 (0.25) to Jun. 2024 (0.00). It may suggest that Curatis Holding AG is progressively becoming less dependent on debt to grow their business.


Curatis Holding AG LT-Debt-to-Total-Asset Historical Data

The historical data trend for Curatis Holding AG's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curatis Holding AG LT-Debt-to-Total-Asset Chart

Curatis Holding AG Annual Data
Trend Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
3.15 0.21 1.11

Curatis Holding AG Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial 0.06 0.21 0.25 1.11 -

Curatis Holding AG LT-Debt-to-Total-Asset Calculation

Curatis Holding AG's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0.133/0.12
=

Curatis Holding AG's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2024 is calculated as

LT Debt to Total Assets (Q: Jun. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2024 )/Total Assets (Q: Jun. 2024 )
=0/55.311
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Curatis Holding AG  (XSWX:CURN) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Curatis Holding AG LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Curatis Holding AG's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Curatis Holding AG Business Description

Traded in Other Exchanges
Address
Weierweg 7, Liestal, CHE, CH-4410
Curatis Holding AG is a specialty pharmaceutical company based in Switzerland. It focus on the acquisition, development and commercialisation of medicines for the prevention, diagnosis and treatment of rare and specialty care diseases. Curatis is engaged in two business areas: Distribution business for orphan disease and specialty care medicines and Development business for orphan and specialty care disease medicines. Its product include Aggrastat (Tirofiban), AmbiFul (Fulvestrant), Brinavess (Vernakalant), Coldistop, Cuprior (Trientin), Cyanokit (Hydroxocobalamin), etc.